Search results
SSRIs and SNRIs for children and adolescents with MDD and/or anxiety disorders are neither a panacea nor contra-indicated. The best available evidence suggests that fluoxetine may be the medication of choice for use in both MDD and anxiety disorders.
- Antidepressant use in children and adolescents: Practice touch points ...
Based on an overview of key review articles and practice...
- Antidepressant use in children and adolescents: Practice touch points ...
8 mar 2024 · Sertraline (Zoloft) and Fluvoxamine (Luvox) are FDA approved for children with OCD (sertraline 6 and older, and fluvoxamine 8 and older). Duloxetine (Cymbalta), which is an SNRI, has FDA approval for anxiety in children and adolescents. All of these are also used for depression.
2 mar 2024 · Which SSRI is right for my child? There are six SSRIs: fluoxetine (Prozac), sertraline (Zoloft), fluvoxamine (Luvox), citalopram (Celexa), escitalopram (Lexapro), and paroxetine (Paxil). In general, they are equally effective and safe, but only four are FDA approved for use in children (escitalopram, fluoxetine, fluvoxamine, and sertraline).
27 paź 2017 · Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) can improve the symptoms of pediatric depression, anxiety, and obsessive-compulsive disorder (OCD), but the benefits and side effects of these medications can vary significantly depending on the disorder, a recent meta-analysis concluded.
This finding is mainly due to the large amount of significant SSRI studies, although patients receiving SNRIs reported significantly more SAEs than did those receiving placebo. Thus, our results support concerns about the safety of antidepressants in children and adolescents.
14 sie 2024 · Selective serotonin reuptake inhibitors (SSRIs) — Medications called selective serotonin reuptake inhibitors (SSRIs) are generally the first-line medication for depression in children and adolescents because most people have only mild (or no) side effects, and the medication is generally taken once per day.
Based on an overview of key review articles and practice guidelines, the present article discusses recent evidence regarding the use of SSRIs to treat depression in children and youth, and risks regarding safety, as well as presents practice touch points to guide management.